Fresenius Medical Care AG & Co. KGaA
Annual Common Assembly 2023
Explanatory assertion by Fresenius Medical Care AG & Co. KGaA (“Firm”) on agenda merchandise 6 “Decision on the approval of the remuneration report for the fiscal yr 2022” and the voting suggestion of Institutional Shareholder Companies Inc. (“ISS”) towards this merchandise for funds to former Chief Govt Officer Dr. Carla Kriwet following her departure
Context
The board of administrators and the supervisory board of the final companion of the Firm, Fresenius Medical Care Administration AG (“normal companion”), and the supervisory board of the corporate have ready a remuneration report for the fiscal yr 2022 (“report” ) and submitted the report back to the Firm’s annual normal assembly 2023 for approval, in accordance with the relevant authorized provisions of the German public restricted firm regulation. The Report, which has been reviewed by the auditor, particulars the compensation advantages awarded or payable within the fiscal yr 2022 to the present and former members of the Administration Board and the Supervisory Board of the Common Associate and the present and former members of the Board of Supervisory Board of Administrators of the Firm.
The remuneration scheme for the remuneration of the Common Associate’s Board of Administrators (the “2020+ Compensation Scheme”) was permitted by the Firm’s 2020 Annual Common Assembly with a vote of 95.05%.
The vote on the report will allow shareholders to deal with any issues that the relevant remuneration system has not been carried out accurately within the respective reporting yr or that info referring to remuneration has not been introduced in a transparent and comprehensible method.
ISS voting suggestion
ISS, in its evaluate of 28 April 2023, testifies to the “good degree of knowledge” of the Report. The remuneration report continues to supply an in depth evaluation of the compensation elements attributed to executives in addition to the relevant variable efficiency targets. The corporate discloses particular and measurable monetary targets inside its variable compensation. Ex submit disclosure relating to efficiency circumstances, revenue sharing plan (STI) funds, LTI funds and general normal degree of transparency goes past market follow.”
On the finish of its evaluation, ISS concludes that “though the corporate’s remuneration report is broadly in keeping with market follow, as a result of above issues relating to termination funds (and others) paid to former Chief Govt Officer Carla Kriwet, one vote towards the remuneration report is taken into account justified.”
1
The Firm absolutely respects the unbiased views and recommendation of ISS relating to voting. The Firm invitations traders to contemplate the next extra info in relation to the issues raised of their determination to approve the Report.
Dr. Carla Kriwet appointment course of
As introduced on March 5, 2022, Dr. Carla Kriwet has been appointed as the brand new CEO of Fresenius Medical Care efficient January 1, 2023. Previous to appointing Dr. Kriwet, the Supervisory Board of the final companion had obtained an summary full together with his {qualifications}, expertise and suitability for the place.
Workplace entry and departure
Dr. Kriwet truly joined the Firm as a member and chairman of the board on October 1, 2022, three months sooner than initially deliberate. For her willingness to take up her place early on October 1, 2022, as an alternative of January 1, 2023, Dr. Kriwet obtained an inaugural bonus of €100 THOUSAND.
Through the fourth quarter of 2022, Dr. Kriwet and the supervisory board of the final companion accountable for appointing the board of administrators developed a number of strategic concepts for the way forward for Fresenius Medical Care, which couldn’t be reconciled. Because the Firm faces plenty of challenges, which it should tackle with a coordinated technique, the administration of the corporate and the administration as an entire should have the same opinion. As emerged through the first weeks following Dr. Kriwet’s inauguration, no settlement might be reached on key strategic points referring to the long run course of the Firm and the required measures on this regard.
On this context and in an effort to keep away from probably everlasting injury to the worth of the Firm, all events concerned have come to the conclusion that it was in the very best pursuits of all events to not proceed the cooperation. Dr Kriwet then resigned from the board at her request and by mutual settlement. Dr. Kriwet’s service contract ended with the tip of the 2022 fiscal yr.
Compensation
Dr. Kriwet was entitled to cost of her fundamental wage of €450 THOUSAND for the interval 1 October 2022 to 31 December 2022. As well as, Dr. Kriwet was entitled to short-term variable compensation for the tax yr 2022 for 176 THOUSAND EUROS, in line with the relative circumstances of the plan and the targets agreed therein. As well as, Dr. Kriwet obtained compensation of €600 THOUSAND for misplaced compensatory advantages from a earlier service relationship, as agreed on the conclusion of her service contract. You stay unaffected by the extra proper to compensation of as much as €1,300 THOUSAND for wage advantages forfeited from a earlier employment relationship, as agreed with Dr. Kriwet on the conclusion of your employment contract; the corresponding funds might fall due in March 2024 and March 2025.
Dr. Kriwet isn’t entitled to the long-term variable pay awarded to her within the 2022 tax yr and isn’t entitled to a pension cost.
It has been agreed with Dr Kriwet that she is entitled to a redundancy cost equal to an annual fundamental wage of €1,800 THOUSAND. A post-contractual non-compete clause has been agreed with Dr. Kriwet for the interval from 6 December 2022 to five December 2024.
2
The charge that Dr. Kriwet receives for the non-competition settlement for the two-year interval following the employment relationship quantities to €1,800 THOUSAND. The post-contractual non-competition clause is customary and can also be a part of Dr. Kriwet’s employment contract. The post-contractual non-compete clause couldn’t truly be agreed with out compensation. Dr. Kriwet had already spent weeks and months familiarizing herself with the problems and changing into acquainted with the Firm and its enterprise mannequin, in addition to the trade wherein the Firm operates, earlier than taking up her place. It was and is due to this fact within the Firm’s curiosity to stick to the post-contractual non-competition settlement in an effort to shield delicate info.
Lastly, Dr. Kriwet has the fitting to make use of her firm automobile for the interval as much as 5 December 2024. Moreover, it has been agreed with Dr. Kriwet that she can be reimbursed for the authorized consultancy charges she withheld in reference to upon his departure Board of Administrators. Licensed use of the corporate automobile and reimbursement of authorized prices are each customary.
Remaining consideration
With its intervention, the Supervisory Board of the final partnership demonstrated its capability to react shortly and to take decisive corrective measures. The Firm has detailed the monetary phrases of the termination settlement with Dr. Kriwet within the Report that’s for approval by the Firm’s shareholders on the 2023 Annual Common Assembly. Total, the Firm views the end result of this termination anticipated unplanned collaboration with Dr. Kriwet and subsequent appointment of Ms. Helen Giza as Chairman of the Common Associate’s Board in the very best pursuits of the Firm’s shareholders.
As highlighted within the Report, the remuneration acknowledged and as a result of members of the Administration Board within the fiscal yr 2022 was decided in accordance with the 2020+ Compensation System and the associated suggestions of the German Company Governance Code. This additionally applies to the remuneration granted or attributable to Dr. Kriwet.
The overall companion and the Supervisory Board of the Firm due to this fact suggest to approve the remuneration report for the fiscal yr 2022.
3
